Brief: Allakos Announces Topline Phase 3 Data From The Eodyssey Study In Patients With Eosinophilic Duodenitis

Allakos

09/09/2022 12:09

Sept 9 (Reuters) - Allakos Inc  ALLK.O :
    * ALLAKOS ANNOUNCES TOPLINE PHASE 3 DATA FROM THE EODYSSEY
STUDY
IN PATIENTS WITH EOSINOPHILIC DUODENITIS
    * ALLAKOS INC - LIRENTELIMAB MET HISTOLOGIC CO-PRIMARY
ENDPOINT
BUT MISSED SYMPTOMATIC CO-PRIMARY ENDPOINT
    * ALLAKOS INC - TRIAL DID NOT ACHIEVE STATISTICAL
SIGNIFICANCE ON
PATIENT REPORTED SYMPTOMATIC CO-PRIMARY ENDPOINT
    * ALLAKOS INC - NOT PLANNING TO CONDUCT ADDITIONAL STUDIES
IN
EOSINOPHILIC GASTROINTESTINAL DISEASES, BUT MAY DO SO IN FUTURE
    * ALLAKOS INC - FOCUSING DEVELOPMENT EFFORTS FOR
LIRENTELIMAB IN
ATOPIC DERMATITIS AND CHRONIC SPONTANEOUS URTICARIA AND ON AK006

Source text for Eikon:  ID:nGNX4KKpyR 
Further company coverage:  ALLK.O 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))